Manfred Schmitt Selected Research

Urokinase-Type Plasminogen Activator (Urokinase)

7/2016	Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
1/2016	uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
4/2015	Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221.
8/2014	uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
4/2014	Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.
12/2012	Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes.
12/2011	Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine.
7/2011	Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
6/2011	Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
11/2010	Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Manfred Schmitt Research Topics

Disease

111	Neoplasms (Cancer) 01/2021 - 01/2002
68	Breast Neoplasms (Breast Cancer) 12/2018 - 01/2002
33	Neoplasm Metastasis (Metastasis) 06/2017 - 01/2002
29	Ovarian Neoplasms (Ovarian Cancer) 10/2018 - 09/2002
9	Carcinoma (Carcinomatosis) 01/2015 - 02/2002
5	Triple Negative Breast Neoplasms 03/2018 - 01/2016
4	Disease Progression 10/2010 - 06/2004
3	Residual Neoplasm 06/2018 - 03/2007
3	Ascites 03/2007 - 06/2003
2	Carcinogenesis 01/2017 - 04/2013
2	Circulating Neoplastic Cells 10/2012 - 01/2009
2	HELLP Syndrome 11/2009 - 04/2005
2	Meningeal Carcinomatosis 09/2008 - 01/2007
2	Hypoxia (Hypoxemia) 05/2007 - 01/2006
2	Squamous Cell Carcinoma of Head and Neck 01/2006 - 06/2005

Drug/Important Bio-Agent (IBA)

38	Proteins (Proteins, Gene)FDA Link 10/2018 - 01/2002
38	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 07/2016 - 01/2002
35	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2002
32	Plasminogen Activator Inhibitor 1IBA 07/2016 - 01/2002
22	Messenger RNA (mRNA)IBA 10/2018 - 04/2003
22	Serine Proteases (Serine Protease)IBA 06/2018 - 01/2002
19	Peptide Hydrolases (Proteases)FDA Link 10/2018 - 01/2003
16	Biological ProductsIBA 04/2011 - 08/2002
15	Kallikreins (Kallikrein)IBA 10/2018 - 06/2003
14	Hormones (Hormone)IBA 01/2017 - 01/2002
14	Tissue ExtractsIBA 01/2016 - 01/2002
12	Plasminogen InactivatorsIBA 12/2011 - 01/2002
11	SteroidsIBA 01/2017 - 01/2002
11	AntigensIBA 01/2016 - 08/2002
10	PlasminogenIBA 07/2016 - 01/2002
10	EnzymesIBA 04/2014 - 02/2002
9	Urokinase Plasminogen Activator ReceptorsIBA 07/2016 - 11/2002
8	AnthracyclinesIBA 12/2018 - 01/2009
8	LigandsIBA 06/2017 - 11/2002
8	Estrogen ReceptorsIBA 07/2016 - 07/2004
8	Tumor Biomarkers (Tumor Markers)IBA 01/2013 - 11/2004
7	Tissue Kallikreins (Tissue Kallikrein)IBA 10/2018 - 02/2006
7	Indicators and Reagents (Reagents)IBA 11/2009 - 06/2003
7	Tamoxifen FDA LinkGeneric 10/2009 - 07/2004
6	Transcription Factors (Transcription Factor)IBA 11/2018 - 07/2003
6	ImmunosorbentsIBA 01/2006 - 02/2002
5	Trastuzumab (Herceptin)FDA Link 01/2021 - 01/2003
5	ParaffinIBA 12/2018 - 11/2008
5	IntegrinsIBA 08/2009 - 07/2003
5	VitronectinIBA 08/2009 - 07/2003
4	Formaldehyde (Formol)FDA Link 12/2018 - 11/2008
4	DNA (Deoxyribonucleic Acid)IBA 10/2016 - 04/2006
4	Biological FactorsIBA 11/2011 - 01/2002
4	Peptides (Polypeptides)IBA 07/2011 - 09/2002
4	RNA (Ribonucleic Acid)IBA 11/2009 - 04/2006
3	Cathepsin BIBA 06/2017 - 01/2016
3	ChemokinesIBA 06/2017 - 02/2012
3	Estrogens (Estrogen)FDA Link 01/2017 - 11/2003
3	Fibrinolysin FDA Link 01/2017 - 11/2002
3	Plasminogen Activators (Plasminogen Activator)IBA 07/2016 - 08/2002
3	matrigelIBA 08/2012 - 07/2003
3	Extracellular Matrix ProteinsIBA 08/2012 - 02/2008
3	Fluorouracil (Carac)FDA LinkGeneric 12/2011 - 12/2003
3	Matrix Metalloproteinases (MMPs)IBA 04/2011 - 07/2003
3	Integrin alphaVbeta3IBA 08/2009 - 03/2005
3	Cyclic PeptidesIBA 01/2003 - 09/2002
2	Cysteine Proteases (Cysteine Protease)IBA 06/2017 - 07/2003
2	Oncogene Proteins (Oncogene Protein)IBA 01/2017 - 08/2010
2	PlatinumIBA 10/2016 - 03/2007
2	human ERBB2 proteinIBA 07/2016 - 12/2009
2	Y-Box-Binding Protein 1IBA 07/2016 - 12/2009
2	Progesterone Receptors (Progesterone Receptor)IBA 07/2016 - 08/2010
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2016 - 02/2012
2	Dinoprostone (PGE2)FDA Link 01/2016 - 02/2012
2	Celecoxib (Celebrex)FDA Link 01/2016 - 02/2012
2	Indomethacin (Indometacin)FDA LinkGeneric 01/2016 - 02/2012
2	Protein Isoforms (Isoforms)IBA 04/2015 - 04/2011
2	MicroRNAs (MicroRNA)IBA 04/2015 - 12/2013
2	Epithelial Cell Adhesion MoleculeIBA 10/2012 - 01/2003
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2011 - 11/2009
2	Levonorgestrel (Plan B)FDA LinkGeneric 07/2011 - 11/2010
2	AntibodiesIBA 04/2010 - 01/2003
2	Methotrexate (Mexate)FDA LinkGeneric 11/2009 - 09/2008
2	FibrinIBA 11/2009 - 09/2004
2	Metalloproteases (Metalloproteinases)IBA 09/2009 - 11/2008
2	integrin-linked kinaseIBA 08/2009 - 07/2003
2	Insulysin (Insulin-Degrading Enzyme)IBA 11/2008 - 10/2008
2	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 08/2005 - 12/2003
2	Pharmaceutical PreparationsIBA 04/2005 - 12/2003
2	Complementary DNA (cDNA)IBA 07/2003 - 02/2002
2	Silicon Dioxide (Silica)FDA LinkGeneric 01/2003 - 01/2002
2	Cell Surface ReceptorsIBA 01/2003 - 01/2002
1	Chemokine CX3CL1IBA 01/2021
1	CytokinesIBA 06/2017
1	estropipate (Ogen)FDA LinkGeneric 01/2017
1	kallikrein 4IBA 01/2017
1	Progesterone FDA LinkGeneric 01/2017

Therapy/Procedure

45	Therapeutics 01/2021 - 01/2002
16	Drug Therapy (Chemotherapy) 12/2018 - 01/2002
10	Adjuvant Chemotherapy 03/2018 - 08/2002
7	Orthopedic Procedures 04/2011 - 11/2003
6	Replantation 04/2011 - 08/2004
2	Lasers (Laser) 01/2015 - 11/2014
2	Radiotherapy 08/2010 - 01/2007
1	Combination Drug Therapy (Combination Chemotherapy) 01/2017